Abstract
Famotidine and selected H2-antagonists were evaluated with respect to toxicity and selected pharmacological activities. When administered intraperitoneally to mice at a dose equivalent to 10 times their respective H2-antagonist ED50 values, no deaths were observed. Similarly, no alteration in brain ACh concentrations or overt pharmacological effects were noted. However, at 400 mg/kg, ranitidine produced 89% lethality, followed by cimetidine (11%) and famotidine. Only cimetidine and famotidine at this dose significantly elevated brain acetylcholine levels. These results do not correlate with the in vitro data, where ORF-17578 and ranitidine were the most potent entities with respect to acetylcholinesterase inhibition (∼1–2 × 10−6 M), followed by nizatidine > cimetidine > famotidine. The sulfoxide metabolites of ranitidine and cimetidine were approximately one-tenth as potent as their parent compounds with respect to inhibition of acetylcholinesterase. Direct muscarinic stimulation or potentiation of acetylcholine-induced contraction in ileal tissue was not observed for any of the H2-antagonists.
Similar content being viewed by others
REFERENCES
J. M. Thomas and G. Misiewicz. Clin. Gastroenterol. 13:501–541 (1984).
G. Bertaccini, G. Coruzzi, E. Poli, and M. Adams. Agents Actions 19:180–187 (1986).
T. O. G. Kovacs, G. M. Van Deventer, V. Maxwell, B. Sytnik, and J. H. Walsh. Scand. J. Gastroenterol. 22 (Suppl. 136):41–46 (1987).
L. B. Katz, C. K. Scott, and D. A. Shriver. J. Pharmacol. Exp. Ther. 237:404–410 (1986).
W. E. Hansen and S. Bertl. Arzneim. Forsch. 33:161–163 (1983).
G. Bertaccini and G. Coruzzi. Agents Actions 12:168–171 (1982).
M. C. E. Gwee and L. S. Cheah. Life Sci. 39:383–388 (1986).
R. F. Holdren and R. M. Hixson. J. Am. Chem. Soc. 68:1198–1201 (1946).
R. B. Pendleton, P. G. Cook, A. Shepherd-Rose, and A. W. Mangel. J. Pharmacol. Exp. Ther. 233:64–69 (1985).
G. L. Ellman, K. D. Courtney, V. Andres, Jr., and A. Featherstone. Biochem. Pharmacol. 7:88–95 (1961).
J. W. Kosh and J. J. Freeman. Fed. Proc. 40:270 (1981).
I. Kagevi and L. Wahlby. Lancet 1:164–165 (1985).
I. Kagevi, E. Thorhallsson, and L. Wahlby. Br. J. Clin. Pharmacol. 24:849–850 (1987).
M. Aono, M. Morika, K. Mizuda, H. Narusawa, and H. Uchino. Nippon Shokakibyo Gakkai Zasshi 81:1653 (1984).
S. M. Mehta, D. D. Bhalara, and R. K. Goyal. Agents Actions 21:38–40 (1987).
L. Re, M. L. Cingolani, C. Concettoni, and L. Rossini. Pharmacol. Res. Commun. 15:485–517 (1983).
L. Re and L. Rossini. Pharmacol. Res. Commun. 16:381–399 (1984).
R. T. Brittain, D. Jack, and L. E. Martin. Lancet 1:418 (1983).
Glaxo Inc. Product Information No. 4000714.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kosh, J.W., Sowell, J.W. & Chapman, J.M. A Comparison of the Cholinergic Activity of Selected H2-Antagonists and Sulfoxide Metabolites. Pharm Res 6, 709–713 (1989). https://doi.org/10.1023/A:1015994607652
Issue Date:
DOI: https://doi.org/10.1023/A:1015994607652